NASA Expedition 70 astronaut photograph of northwestern Europe at night, showing the illuminated cities of London, Amsterdam and Paris beneath Earth’s horizon. The scene does not depict NovaPharm operating facilities.

International markets

Medicine
moves globally.
Access is local.

We identify product opportunities, assess local regulatory pathways and develop qualified partnerships for access to medicines across global markets.

Target markets. Local responsibility.

Five regions. Five different pathways.

Product-specific opportunities. Local permissions first.

Photograph of the London skyline and River Thames in the United Kingdom
01   United Kingdom

Our home market.

Building regulatory readiness and qualified supply pathways. Required MHRA authorisations and GDP operating controls must precede regulated supply.

Photograph outside the European Parliament in Brussels, Belgium
02   European Union

Selected partnerships.

Exploring member-state opportunities through locally authorised partners. UK wholesale permissions do not transfer to EU member states.

Photograph of New York City skyline in the United States
03   United States

Local pathways.

Evaluating state-specific licensing and commercial partnerships. Applicable state licences and DSCSA requirements govern prescription wholesale activities.

Photograph of the Toronto waterfront and CN Tower in Canada
04   Canada

Product-specific market routes.

Assessing importer, distributor and product-specific routes. Drug, device and natural-health-product requirements remain distinct.

Photograph of Burj Khalifa and the Dubai skyline in the United Arab Emirates, illustrative of one MENA market
05   Middle East & North Africa

Regional opportunity assessment.

Considering country-specific partnerships, including the UAE and Saudi Arabia. Establishment, import and distribution permissions require local assessment.

These are markets under evaluation, not claims of active regulated pharmaceutical distribution or existing wholesale authorisations across these territories.

Real photograph of packaged medicine tablets illustrating product-specific pharmaceutical market pathways

Expansion discipline

Local permissions.
Shared standards.

For each target market, we assess demand, regulatory requirements, authorised counterparties, commercial viability, product evidence and accountable supply arrangements.

Current regulatory boundary. Regulated pharmaceutical wholesale supply has not commenced. Any future supply depends on required local authorisations, product-specific permissions, qualified suppliers, GDP/quality controls and permitted buyer channels. UK permissions do not confer distribution rights in other countries.

Explore our market-entry approach

Where should medicine go next?

Tell us the product and the market. We will explore the pathway with evidence.

Start a qualified conversation

For qualified B2B organisations. An enquiry is not an offer to supply, an approval or a guarantee of market availability.